Stevanato Group (NYSE:STVN) today announced a collaboration with Recipharm to manufacture pre-fillable syringes for soft mist inhalers.
Piombino Dese, Italy-based Stevanato Group plans to lend manufacturing experience to support production of the syringes. As part of the collaboration, it intends to provide and manufacture its Alba glass pre-fillable syringe. Stevanato Group will assemble Alba with the integrated spray module (ISMTM) of Recipharm’s soft mist inhaler. Together, this creates the “pre-filled syringe inhaler” (PFSITM).
In the partnership, Stevanato Group takes responsibility for the complete primary drug package. Recipharm’s focus centers around the design and manufacture of the spray technology, the inhalation device and the fill/finish effort.
Resyca — a Recipharm and Medspray joint venture — develops, manufactures and licenses Recipharm’s inhaler. Recipharm supplies it as a pre-filled and ready-to-use inhalation device.
How Stevanato Group and Recipharm plan to work together
Stevanato Group said in a news release that the collaboration highlights its “capabilities as a one-stop shop.” The company offers contract drug manufacturing organizations support in their drug development programs from the clinical phase through to market release.
Alba syringes feature an internal coating based on silicone oil, cross-linked with the glass surface. This minimizes sub-visible particle release to ensure superior performance during delivery, Stevanato Group said.
“By leveraging Stevanato Group’s integrated capabilities, from plastic injection molding and assembly capabilities to comprehensive scientific and analytical support services, we will be able to offer a turnkey solution, and accelerate and de-risk our pharmaceutical customers’ development programs,” said Bernhard Muellinger, GM and COO at Resyca. “This is particularly true for novel inhaled biological products.”
Combining Alba with Recipharm’s soft mist inhaler delivers sensitive drug products more efficiently to the respiratory airways, Stevanato Group said. It provides biopharma companies with a containment solution featuring enhanced stability and safety, too.
“Creating a network of strategic collaboration partners is an important element of our long-term strategy to match customers’ needs and address self-administration trends in patient care with user-friendly drug delivery devices that provide variable and accurate dosing,” Stevanato Group CEO Franco Moro said. “This agreement marks another key step in broadening our high-value solutions and integrated capabilities as we continue to diversify and enhance our presence in the drug delivery market of pen injectors, auto-injectors, inhalers, and wearable pods.”